All In Biotech

Drug Trial Radar · NCT00424476

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 865 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

865

Actual

Start

May 2007

Primary completion

May 2009

Study completion Mar 2010

Sponsor

Lead sponsor
Human Genome Sciences Inc.Industry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jan 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • PlaceboDrug

    Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.

  • Belimumab 1 mg/kgDrug

    Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.

  • Belimumab 10 mg/kgDrug

    Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SLE Responder Index (SRI) Response Rate at Week 52Time frame: Baseline, 52 weeks

Locations

92 sites in 13 countries. Site status is shown where the registry gives one.

  • OMI, Organización Médica de Investigación

    Buenos Aires, Argentina

  • CIER, Centro de Investigaciones en Enfermedades Reumáticas

    Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina

  • Hospital General de Agudos Carlos G. Durand

    Buenos Aires, Argentina

  • Centro Privado de Medicina Familiar

    Buenos Aires, Argentina

  • Hospital Sirio Libanes

    Buenos Aires, Argentina

  • Atencion Integral en Reumatologia

    Buenos Aires, Argentina

  • Instituto de Investigaciones Medicas

    Buenos Aires, Argentina

  • Hospital Interzonal General San Martín

    La Plata, Argentina

  • CAICI, Instituto Centralizado de Asistencia e Investigación Clínica Integral

    Rosario, Argentina

  • Centro Medico Privado de Reumatologia

    San Miguel de Tucumán, Argentina

  • Repatriation Hospital

    Daw Park, Australia

  • Emeritus Research, Cabrini Hospital

    Melbourne, Australia

  • Monash Medical Centre

    Melbourne, Australia

  • Royal Perth Hospital

    Shenton Park, Australia

  • Hospital de Clínicas - UNICAMP

    Campinas, Brazil

  • Hospital das Clínicas - Universidade do Paraná

    Curitiba, Brazil

  • Hospital de Clínicas - Universidade Federal de Pernambuco

    Fortaleza, Brazil

  • Hospital Geral de Goiânia

    Goiânia, Brazil

  • Hospital Universitário - Universidade Federal de Juiz de Fora

    Juiz de Fora, Brazil

  • Hospital São Lucas da PUC-RS

    Porto Alegre, Brazil

  • Hospital Universitário Pedro Ernesto - UERJ

    Rio de Janeiro, Brazil

  • Hospital Unversitario Clementino Fraga Filho UFRJ

    Rio de Janeiro, Brazil

  • Hospital Santa Izabel

    Salvador, Brazil

  • Hospital Abreu Sodré

    São Paulo, Brazil

  • Hospital do Servidor Público Estadual de São Paulo - Francisco Morato de Oliveira

    São Paulo, Brazil

  • Hospital Heliópolis

    São Paulo, Brazil

  • Hospital Dr. Sotero del Rio

    Santiago, Chile

  • Pontificia Universidad Católica de Chile

    Santiago, Chile

  • Clínica Dávila

    Santiago, Chile

  • Hospital Dr. Gustavo Fricke

    Viña del Mar, Chile

  • Centro de Reumatologia y Ortopedia

    Barranquilla, Colombia

  • Centrode de Investigaciones en Reumatologia Especialidades Medicas (CIREEH)

    Bogotá, Colombia

  • Fundación Instituto de Reumatología Fernando Chalem

    Bogotá, Colombia

  • Riesgo de Fracturas

    Bogotá, Colombia

  • SERVIMED

    Bucaramanga, Colombia

  • Corporación para Investigaciones Biológicas (CIB)

    Medellín, Colombia

  • Office of Dr. Jose Molina

    Medellín, Colombia

  • Office of Dr. Guzman

    Bogota, Cundinamarca, Colombia

  • Fundación Oftalmologica de Santander Clinica Carlos Ardila Lulle

    Bucaramanga, Santander Department, Colombia

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.